<?xml version="1.0" encoding="UTF-8"?>
<p>Nilotinib was taken twice daily (600 mg/day) for 2 years in the consolidation phase (median dose intensity, 600 mg/day). Patients' outcomes at the end of the consolidation phase at 24 months are summarized in 
 <xref rid="t2-1031835" ref-type="table">Table 2</xref>. Among the 96 patients in the safety analysis set, 18 (18.8%) discontinued the study treatment. The most frequent reason for discontinuation was adverse events; disease progression was not observed in any of the patients.
</p>
